GLP-1 for Men Over 40: Muscle, Testosterone, Cardiovascular Considerations

Men over 40 face a different GLP-1 calculus than younger adults. Sarcopenia (age-related muscle loss) is already happening. Testosterone is declining. Cardiovascular risk is rising. The same medication can produce very different outcomes depending on what surrounds it.

Why men over 40 do well on GLP-1 (in principle)

• Cardiovascular benefit pathway from SELECT is most directly applicable to this group.
• Visceral adipose tissue (the dangerous fat depot) reduces preferentially on GLP-1 therapy.
• Insulin sensitivity improves meaningfully.
• The age-associated drift toward T2D risk is meaningfully reversed.

The muscle problem

Here is the issue everyone underplays. Rapid weight loss from any cause — including GLP-1 — produces substantial loss of lean mass alongside fat mass. The fat-to-lean ratio of weight lost is approximately 70:30 to 75:25 in unsupervised settings. For a man losing 30 lb, that's roughly 8–10 lb of lean mass, much of which is skeletal muscle. At 45, you cannot replace that muscle easily; sarcopenia is already actively progressing.

The solution is not a different drug. The solution is:

• Protein intake: 1.6–2.0 g/kg of target body weight per day. For a 200-lb man targeting 175 lb, that's 130–160 g of protein daily. This is non-negotiable.
• Resistance training: 3–4 sessions per week, prioritizing compound movements (squat, deadlift, bench press, row, overhead press). Sets in the 4–8 rep range build maximum strength; 8–15 rep range builds maximum muscle. You need both. Start where you are, but you need to start.
• Sleep: 7–8 hours. Sleep is when muscle protein synthesis happens. Most busy 40+ men don't get enough.

The goal of GLP-1 therapy in a 40+ man is not "lose 30 lb" — it is "lose 25 lb of fat while gaining or holding muscle." Done right, body composition can improve dramatically. Done wrong, the man at month 12 weighs less but is weaker, less metabolically resilient, and visibly older.

Testosterone

Weight loss from any cause typically raises free testosterone in obese men, often substantially. This effect is well documented and is one reason men over 40 often feel better on GLP-1 beyond what weight loss alone would predict. Baseline morning total testosterone and SHBG before initiation, repeat at 6 months. Many men with prior borderline-low testosterone do not need replacement therapy after meaningful weight loss.

Cardiovascular calculus

For men 40+ with one or more of: family history of premature CAD, hypertension, elevated apoB or LDL, T2D, or known atherosclerosis, the SELECT data are directly applicable. The cardiovascular benefit of semaglutide 2.4 mg is meaningful and emerges within 6 months. For high-cardiovascular-risk men, the conversation is no longer "GLP-1 for weight" — it is "GLP-1 as cardiovascular risk-reduction therapy that also reduces weight."

Alcohol and the "I drink less now" effect

Many men report reduced desire to drink on GLP-1 therapy. The effect is reproducible and beneficial for cardiometabolic, sleep, and recovery outcomes. Account for this — alcohol consumption may drop substantially, with downstream effects on social life. For men whose social life is wrapped around drinking culture, the cognitive shift is real.

What dose and which agent

For men 40+ with significant weight to lose and cardiovascular risk: semaglutide 2.4 mg (or compounded equivalent) at full dose if tolerated. For men with T2D + CV disease: branded Ozempic through insurance is frequently superior because of the CV-indication labeling and prescriber familiarity. Tirzepatide may produce larger weight losses but does not yet have an FDA-approved CV indication; this may change in 2026 when SURPASS-CVOT reads out.

Common pitfalls

• "I'll get the weight off then deal with the muscle later." You won't. Muscle loss during the weight-loss phase is much harder to reverse than gained during it.
• Skipping resistance training because "I don't lift weights." Bodyweight squats, push-ups, and rows count. Start there.
• Eating less protein because appetite is suppressed. This is the most common error. Protein intake should be a deliberate target, not a residual of reduced appetite.
• Stopping at year 1 because "I hit my number." Weight regain after stopping is well documented (STEP-4). This is generally long-term therapy.

Provider considerations

For a 40+ man considering a telehealth GLP-1 program, ask: (1) Will the program include or coordinate body-composition monitoring? (2) Do they require baseline labs including lipid panel, A1c, testosterone, and basic metabolic panel? (3) What is their dose-escalation protocol and how flexible is it? See our NexLife review for an example of how a top-rated cash-pay program structures these elements.